Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus CEFTAZIDIME IN DEXTROSE CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus CEFTAZIDIME IN DEXTROSE CONTAINER.
CEFOBID vs CEFTAZIDIME IN DEXTROSE CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
1-2 g intravenously every 8 hours.
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic